| 41st week of 2015 patent applcation highlights part 8 |
| Patent application number | Title | Published |
|---|
| 20150283121 | TABLET FORMULATIONS CONTAINING 8-[-METHYL]-8-PHENYL-1,7-DIAZA-SPIRO[4.5]DECAN-2-ONE SALTS AND TABLETS MADE THEREFROM - Pharmaceutical formulations containing a salt of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one, represented by Formula I, which are suitable for forming into a tablet dosage form, as well as tablet dosage forms are disclosed. Disclosed also are methods of treatment utilizing such dosage forms. | 2015-10-08 |
| 20150283122 | PHARMACEUTICAL INTERVENTION AND METHOD FOR TREATING AN APRAXIA OF SPEECH IN CHILDREN - A pharmaceutical intervention and therapeutic method for treating an apraxia of speech in children. The child can also be diagnosed with gait abnormalities or impairment autism, mental retardation and dyslexia. If the child demonstrates at least an 18 to 24 month development stage of either verbal development or non-verbal development, a therapeutic dose of a dopamine agonistic, particularly a nonlinear lower alkyl phenidate or dextro-threo-methylphenidate is administered to the child. | 2015-10-08 |
| 20150283123 | INTRANASAL SPRAY DEVICE CONTAINING PHARMACEUTICAL COMPOSITION - An intranasal spray device contains a composition for the intranasal delivery of fentanyl or a pharmaceutically acceptable salt thereof to an animal includes an aqueous solution of fentanyl or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive selected from (i) a pectin and (ii) a poloxamer and chitosan or a salt or derivative thereof; provided that when the composition comprises a pectin it is substantially free of divalent metal ions; and which, in comparison to a simple aqueous solution of fentanyl administered intranasally at the same dose, provides a peak plasma concentration of fentanyl (C | 2015-10-08 |
| 20150283124 | Immunomodulatory Compounds for the Restoration of Vitamin D Sensitivity in Vitamin D Resistant Tumor Cells - Provided herein are methods of restoring vitamin D sensitivity in tumor cells that are vitamin D resistant. Also provided are methods of treating, preventing or managing cancer using an immunomodulatory compound in combination with a vitamin D agent. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods provided herein are also disclosed. | 2015-10-08 |
| 20150283125 | HETEROARYL COMPOUNDS AS 5-HT4 RECEPTOR LIGANDS - The present invention relates to novel compounds of formula (I), and their pharmaceutically acceptable salts and compositions containing them. | 2015-10-08 |
| 20150283126 | METHOD OF MANAGING UROLITHIASIS AND RELATED UROLOGICAL DISORDERS - The present disclosure relates to a method of managing urolithiasis or related urological disorders in a subject in need thereof, using pharmaceutical composition comprising trigonelline or its derivative(s) and 4-hydroxyisoleucine or its derivative(s), optionally along with excipient(s). | 2015-10-08 |
| 20150283127 | SAQUINAVIR-NO FOR IMMUNOMODULATION - The nitric ester of Saquinavir, or its non-toxic salts, solvates or crystalline/polymorphic forms, I useful in the treatment of autoimmune diseases, particularly in disease mediated by pro-inflammatory cytokines. Examples of diseases which may be treated include idiopathic Addison's disease, autoimmune hepatitis, biliary cirrhosis, primary sclerosing cholangitis, Guillain Barré syndrome, Hashimoto's thyroiditis, psoriasis, rheumatoid arthritis, Sjogren's syndrome, systemic lupus erythematous, Type 1 diabetes mellitus and uveitis of ischemia-reperfusion, graft versus host diseases, graft rejection, endo and exo-toxemia and gouty arthritis. | 2015-10-08 |
| 20150283128 | Pharmaceutical Formulation Containing Gelling Agent - Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. | 2015-10-08 |
| 20150283129 | Pharmaceutical Formulation Containing Gelling Agent - Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. | 2015-10-08 |
| 20150283130 | Pharmaceutical Formulation Containing Gelling Agent - Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. | 2015-10-08 |
| 20150283131 | PHARMACEUTICAL COMPOSITIONS CONTAINING PIPERAZINE COMPOUNDS IN COMBINATION WITH A P450 INHIBITOR AND METHODS OF TERMINATING ACUTE EPISODES OF CARDIAC ARRHYTHMIA, RESTORING NORMAL SINUS RHYTHM, PREVENTING RECURRENCE OF CARDIAC ARRHYTHMIA AND MAINTAINING NORMAL SINUS RHYTHM IN MAMMALS THROUGH ADMINISTRATION OF SAID COMPOSITIONS - Disclosed embodiments are related to compositions of a piperazine compound and a P450 inhibitor, including compositions of a piperazine compound and one or more P450 inhibitors, and one or more diluents, disintegrants, binders and lubricants, and the processes for their preparation thereof. | 2015-10-08 |
| 20150283132 | MOLECULES FOR ADMINISTRATION TO ROS1 MUTANT CANCER CELLS - Substituted indazole derivatives of formula (I) or formula 2.(I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful in therapy in the treatment of diseases associated with a deregulated protein kinase activity, like cancer. | 2015-10-08 |
| 20150283133 | LIPOSOMAL CIPROFLOXACIN FORMULATIONS WITH ACTIVITY AGAINST NON-TUBERCULOUS MYCOBACTERIA - Methods of treatment of NTM lung infections using formulations of liposomal ciprofloxacin. Specific liposome formulations and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described. | 2015-10-08 |
| 20150283134 | Benzamides - The present invention is directed to benzamide containing compounds which inhibit the P2X7 receptor | 2015-10-08 |
| 20150283135 | Combinations Of A Pyrimidine Containing NNRTI With RT Inhibitors - The present invention concerns combinations of a pyrimidine containing NNRTI with nucleoside reverse transcriptase inhibitors and nucleotide reverse transcriptase inhibitors useful for the treatment of HIV infected patients or for the prevention of HIV transmission or infection. | 2015-10-08 |
| 20150283136 | PHARMACEUTICAL COMBINATION COMPRISING A B-RAF INHIBITOR AND A HISTONE DEACETYLASE INHIBITOR AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES - A pharmaceutical combination comprising (a) a B-Raf inhibitor and (b) a histone deacetylase inhibitor; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination. | 2015-10-08 |
| 20150283137 | 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of hepatocellular carcinoma (HCC) - 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile or a pharmaceutically acceptable salt and/or solvate thereof for the use for the treatment of hepatocellular carcinoma (HCC). | 2015-10-08 |
| 20150283138 | COMBINED TREATMENT FOR CANCER RESISTANT TO AN EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR - The present invention provides a method for treating a cancer, comprising (a) identifying a patient with acquired resistance to an EGFR kinase inhibitor; and (b) administering to the patient an anti-cancer agent, and treating the patient with radiation therapy. | 2015-10-08 |
| 20150283139 | CANCER TREATMENT METHOD - Disclosed herein is a method of treating breast cancer that has metastasized to the brain in a mammal by administration of 4-quinazolinamines and pharmaceutical compositions containing the same. In particular, the method relates to methods of treating breast cancer brain metastases which overexpress erbB2 by administration of N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine and salts and solvates thereof. | 2015-10-08 |
| 20150283140 | USE OF SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY - The present invention refers to the use of sodium channel blockers such as tetrodotoxin or saxitoxin, its analogues/derivatives as well as their acceptable salts, for the production of a medicament for the treatment of neuropathic pain resulting from chemotherapy. | 2015-10-08 |
| 20150283141 | MACROCYCLIC FLT3 KINASE INHIBITORS - The present invention relates to macrocylic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of FLT3 (FMS-Related Tyrosine kinase 3). Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine, in particular for the treatment of cell proliferative disorders, such as cancer. | 2015-10-08 |
| 20150283142 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS - Provided herein are methods, kits, and pharmaceutical compositions that include a PI3 kinase inhibitor for treating cancers or hematologic disorders. | 2015-10-08 |
| 20150283143 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTING AND TREATING RENAL IMPAIRMENT - The present invention relates to methods for treating and preventing renal impairment by administering to a subject a therapeutically effective amount of an A | 2015-10-08 |
| 20150283144 | METHODS AND COMPOSITIONS FOR STIMULATING BENEFICIAL BACTERIA IN THE GASTROINTESTINAL TRACT - The invention relates to supporting the growth or maintenance of oxygen-sensitive bacteria in the gastrointestinal tract of an animal. Provided is the use of riboflavin, riboflavin phosphate or a salt thereof, for the manufacture of a food composition, pharmaceutical composition, food or dietary supplement, for the selective stimulation of | 2015-10-08 |
| 20150283145 | TREATMENT OF HYPERPROLIFERATIVE AND PRE-CANCEROUS SKIN DISEASES USING AN INHIBITOR OF CBP/CATENIN - The present disclosure relates generally to alpha-helix mimetic structures and specifically to alpha-helix mimetic structures that are inhibitors of β-catenin. The disclosure also relates to applications in the treatment of hyperproliferative and pre-cancerous skin conditions including actinic keratosis and psoriasis, and pharmaceutical compositions comprising such alpha helix mimetic β-catenin inhibitors. | 2015-10-08 |
| 20150283146 | TRIAZINE DERIVATIVES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE - A compound of formula (I) for use in the treatment of a condition or disorder associated with nicotinamide adenine dinucleotide phosphate oxidase. | 2015-10-08 |
| 20150283147 | TREATING POLYCYSTIC KIDNEY DISEASE WITH HSP90 INHIBITORY COMPOUNDS - Provided are methods of treating polycystic kidney disease in a subject in need thereof, by administering to the subject in need thereof, an effective amount of a compound according to formula (I) or a pharmaceutically acceptable salt thereof, wherein the variables in the structural formulae are defined herein. Also provided are methods of treating polycystic kidney disease by a compound of formula (I) in combination with additional therapeutic agents. | 2015-10-08 |
| 20150283148 | ARRANGEMENT OF SPECIFIC ANTIDOTES WITH ALLOPATHIC MEDICINAL PREPARATIONS IN GENERAL SECONDARY PACKAGE - The invention relates to the area of medicine, namely to the medicinal preparations, applied in clinical practice. The proposed medicinal preparation contains two non-miscible components, one allopathic medicinal preparation, and the second one is a homeopathic medicinal preparation. It features the second component obtained by potentiating of the first component diluted within the range from 6C to 30C and placed into blisters, con bottles, ampoules in the general secondary package with an allopathic component. Upon the termination or cancellation of an allopathic treatment course, the use of specific antidote—homeopathic component corrects the side effects, reduces the allergic reactions, accelerates the restorative processes in organism. | 2015-10-08 |
| 20150283149 | METHODS OF TREATING PATIENTS HAVING IMPLANTABLE CARDIAC DEVICES - Described herein are methods for reducing ventricular tachycardia/ventricular fibrillation (VT/VF), methods for reducing implantable cardioverter-defibrillator device (ICD) shocks, methods for reducing CV hospitalization, ER visits, CV death or SCD in patients having implantable cardiac devices or CRT, and methods for reducing the use of ICD in a human patient without prior VT/VF, by administering an effective amount of the potent and selective late sodium ion channel blocker Compound 1. | 2015-10-08 |
| 20150283150 | INTRACMERAL SUSTAINED RELEASE THERAPEUTIC AGENT IMPLANTS - Described herein are intracameral implants including at least one therapeutic agent for treatment of at least one ocular condition. The implants described herein are not anchored to the ocular tissue, but rather are held in place by currents and gravity present in the anterior chamber of an eye. The implants are preferably polymeric, biodegradable and provide sustained release of at least one therapeutic agent to both the trabecular meshwork and associated ocular tissue and the fluids within the anterior chamber of an eye. | 2015-10-08 |
| 20150283152 | Levonorgestrel-Only-Composition For Optimized Oral Contraception With Defined Levonorgestrel Content, Dosage Regimen And Pharmaceutical Preparation - Based on specific experimental studies the invention relates to an optimized levonorgestrel-only-composition for improved continuous oral contraception with consequences for suitable pharmaceutical preparations for the same purpose and with defined levonorgestrel content. | 2015-10-08 |
| 20150283153 | PHARMACEUTICAL COMPOSITION - A pharmaceutical composition comprising: (A) an androgen; (B) a cyclic enhancer of the type used in the compositions and methods claimed by U.S. Pat. No. 5,023,252 to Hsieh; and (C) a thickening agent; including, for example, a composition in which the cyclic enhancer is a macrocyclic ester or a macrocyclic ketone; the use of the composition to treat a condition, for example, male hypogonadism, in a patient by applying the composition to the membrane of the patient; and a method for making the composition. | 2015-10-08 |
| 20150283154 | METHODS OF INHIBITING VASCULAR PERMEABILITY AND APOPTOSIS - Agonists of vascular endothelial sphingosine-1-phosphate receptors are described. Compounds such as FTY720 can be phosphorylated by sphingosine kinase-2 into the phosphorylated forms which serve as sphingosine-1-phosphate receptor agonists. The vascular endothelial sphingosine-1-phosphate receptor agonists are employed in methods of treating a mammal for vascular permeability disorders and unwanted vascular endothelial cell apoptosis, and for the growth of new blood vessels. The sphingosine-1-phosphate receptor agonists can be used for the manufacture of a medicament for treating vascular permeability disorders and unwanted vascular endothelial cell apoptosis, and for the growth of new blood vessels | 2015-10-08 |
| 20150283155 | FOSFESTROL FOR USE IN CURATIVE OR PALLIATIVE TREATMENT OF PROSTATE CANCER - The present invention relates to the use of Fosfestrol (diethylstilbestrol diphosphate) in a method of curative or palliative treatment of prostate cancer in male mammals, said method comprising orally administering Fosfestrol in a daily dosage of at least 1,000 mg. The inventors have discovered that Fosfestrol when administered in very high oral dosages is effective in the treatment of prostate cancer, especially hormone resistant prostate cancer, without giving rise to serious side effects, such as thromboembolic toxicity or mortality. The invention further provides an oral dosage unit comprising at least 500 mg, of Fosfestrol. | 2015-10-08 |
| 20150283156 | COMPOSITIONS AND FORMULATIONS OF GLUCOSAMINE FOR TRANSDERMAL AND TRANSMUCOSAL ADMINISTRATION - Disclosed are compositions and formulations comprising glucosamine or a pharmaceutically acceptable salt thereof for use in the treatment of joint conditions and adapted for use in a bath or soak or bath beads, powders, salts, and oils, kits, and methods of treatment using the same. Also disclosed are lozenges, suppositories, patches, and topical creams comprising glucosamine or a pharmaceutically acceptable salt thereof for use in the treatment of joint conditions and methods of treatment using the same. In some embodiments the joint conditions include osteoarthritis. | 2015-10-08 |
| 20150283157 | HYPERSULFATED DISACCHARIDES TO TREAT ELASTASE RELATED DISORDERS - Hypersulfated disaccharides of formula I and other hypersulfated disaccharides disclosed herein are used to treat diseases or conditions associated with human neutrophil elastase imbalances. The disaccharides and/or intermediates useful to prepare such compounds are prepared from heparin. The diseases and conditions which are treated with a compound of formula I include chronic obstructive pulmonary disorder (COPD) and cystic fibrosis (CF). The formulations are delivered to the lungs in an aerosol formulations or dry powder means or via nebulization. Oral forms are also suitable. | 2015-10-08 |
| 20150283158 | Ganglioside Transmucosal Formulations - A transmucosal formulation comprising a ganglioside and a mucosal absorption enhancer, as well as a method of treating or preventing Parkinson's disease in a human patient in need thereof comprising parenterally administering such a transmucosal formulation to said patient. | 2015-10-08 |
| 20150283159 | ANTICANCER AGENT, AND COMBINATION USE ANTICANCER AGENT - An anticancer agent containing ellagitannin, a combination use anticancer agent wherein the anticancer agent and an anticancer agent containing anthracyclines are used in combination. | 2015-10-08 |
| 20150283160 | Controlled Release Systems of Pluribioactive Antifungal Drugs - Controlled release systems release at least one pluribioactive antifungal drug exhibiting at least one additional bioactivity from the group consisting of spermiostatic, antineoplastic, antibacterial, antirestenotic and antiviral activities. The drug release system is designed for use as a spermiostatic contraceptive, intravaginal ringed-mesh which may also exhibit antiviral activity, an in situ-forming implant for treating different forms of cancer and topical film for treating or preventing bacterial and fungal infections. | 2015-10-08 |
| 20150283161 | Compositions Comprising S-Adenosylmethionine and a Gallic Acid Ester - Provided herein are compositions and formulations comprising S-adenosyl-L-methionine (“SAM-e” or “SAMe”) and one or more gallic acid esters. Also provided herein are methods for improving the delivery of SAMe. Compositions and formulations provided herein increase SAMe plasma concentrations and area under the curve (AUC) values. Also provided herein are methods of treating a disease or disorder in a subject by administering compositions or formulations comprising exogenous SAMe and one or more gallic acid esters. | 2015-10-08 |
| 20150283162 | MYOCARDIAL PERFUSION IMAGING METHODS AND COMPOSITIONS - A myocardial imaging method that is accomplished by administering one or more adenosine A | 2015-10-08 |
| 20150283163 | MUSCLE TREATMENT COMPOSITION AND METHOD MAKING SAME - A topical treatment composition for treating muscle cramps, muscle stiffness, muscle pain or muscle spasms. The treatment composition includes a middle (mid) chain fatty acid (MCFA). A method of making the topical treatment composition is also disclosed herein. | 2015-10-08 |
| 20150283164 | Treatment of Myelodysplastic Syndrome by Inhibition of NR2F2 - Methods, compositions, and treatment protocols are provided in the current invention for the treatment of myelodysplastic syndrome (MDS) through the inhibition of NR2F2 gene expression or activity of protein. In one embodiment silencing, or substantial inhibition of NR2F2 expression is achieved through induction of RNA interference in cells associated with development of MDS. Induction of differentiation or stimulation of apoptosis as a result of NR2F2 inhibition may be used to reduce the state of MDS, and/or in other embodiments to inhibit or revert progression to leukemic states. | 2015-10-08 |
| 20150283165 | USE OF AN INHIBITOR OF IRS-1 FOR TREATING SKIN DISORDERS - The present invention relates to an inhibitor of the expression of IRS-1 for treating an angiogenic and/or inflammatory skin disease. The present invention also relates to a transdermal composition, preferably an ointment, comprising an inhibitor of the expression of IRS-1, and to the use thereof for treating an angiogenic and/or inflammatory skin disease. | 2015-10-08 |
| 20150283166 | SYNERGISTIC ANTI-CANCER COMPOSITION AND A PROCESS FOR THE PREPARATION THEREOF - The present invention provides an anti-cancer lipid-based composition that kills very aggressive pancreatic cancer cells and breast cancer stem cell (CSC)-like cells. This composition is a concoction of an anti-cancer agent, ESC8 and a glucocorticoid receptor (GR)-targeting cationic lipid delivery system, DX which is further complexed with plasmid DNA. This composition shows anti-cancer effect and initiates killing of cancer cells and CSC-like cells within 3 h. When anti-cancer gene encoded plasmid is used, residual cancer cells were also significantly eradicated after 2 days of exposure. The formulation-free naked ESC8 requires at least ten-fold more concentration and 3 days of continuous treatment to get a similar level of killing. The composition could also inhibit the tumor growth in mice orthotopically implanted with very aggressive mouse breast cancer cell, ANV-1. This cell is known to produce breast CSC-like cells that show phenotype of advanced cancer relapsing. There is no visible toxic effect of this composition when injected in mice, indicating that it has minimum to no toxic effect to normal homeostasis. The present invention is likely to find specific application in developing potential therapeutic treatment for aggressive cancers and CSC-like cancers. | 2015-10-08 |
| 20150283167 | THERAPEUTIC TREATMENTS BASED ON ADMINISTRATION OF SMALL RNA FRAGMENTS - This invention provides therapeutic treatments that prevent or ameliorate thrombocytopenia based on administration of small RNA fragments. More specifically, this invention provides an improved chemotherapeutic regimen that prevents or ameliorates bone marrow suppression and thrombocytopenia induced by anti-cancer drugs, wherein the chemotherapeutic regimen incorporates administration of small RNA fragments. Further, the present invention provides a therapeutic treatment for thrombocytopenia associated with immune disorders known as Immune Thrombocytopenic Purpura based on administration of small RNA fragments. | 2015-10-08 |
| 20150283168 | INJECTABLE CHITOSAN MIXTURES FORMING HYDROGELS - A chitosan composition which forms a hydrogel at near physiological pH and 37° C., comprising at least one type of chitosan having a degree of acetylation in the range of from about 30% to about 60%, and at least one type of chitosan having a degree of deacetylation of at least about 70% is disclosed. Further disclosed is a chitosan composition which forms a hydrogel at near physiological pH and 37° C., that includes at least one type of chitosan having a degree of deacetylation of at least about 70% and a molecular weight of from 10-4000 kDa, and at least one type of a chitosan having a molecular weight of from 200-20000 Da. Further disclosed are methods of preparation and uses of the chitosan compositions. | 2015-10-08 |
| 20150283169 | PHARMACEUTICAL AGENT HAVING LONG-LASTING EFFECT OF TREATING ARTHRITIC DISORDERS - The present invention relates to an injection solution for intra-articular administration for treating arthritic disorders comprising a cross-linked hyaluronic acid derivative wherein part of functional groups of a hyaluronic acid are cross-linked with a cross-linking group to the extent of 0.6 to 15% of cross-linking extent as an active ingredient in an amount having a long-lasting analgesic effect and a pharmaceutically acceptable carrier, and an analgesic composition for suppressing a cartilage degeneration caused by arthritic disorders or a composition for suppressing a cartilage degeneration or an inflammation of synovium caused by arthritic disorders each comprising the cross-linked hyaluronic acid derivative and a pharmaceutically acceptable carrier. | 2015-10-08 |
| 20150283170 | COATED PHARMACEUTICAL COMPOSITIONS - The present invention relates to polycarbophil coated crosslinked amine polymers and/or pharmaceutical compositions comprising polycarbophil coated crosslinked amine polymers. The polycarbophil coated crosslinked amine polymers have several therapeutic applications, including, but not limited to, hyperphosphatemia, chronic kidney disease and End-Stage Renal Disease. | 2015-10-08 |
| 20150283171 | POLYMERS FOR REVERSING HEPARIN-BASED ANTICOAGULATION - Embodiments presented herein relate to various polymers. Some of the polymer embodiments are heparin binding polymers. Some embodiments of the heparin binding polymers can be employed to bind to heparin for methods such as separating, purifying, removing, and/or isolating heparin and heparin like molecules. | 2015-10-08 |
| 20150283172 | PHARMACEUTICAL COMPOSITION FOR THE PREPARATION OF INFUSION SOLUTIONS OF ANTIMICROBIAL PREPARATIONS, ITS PRODUCTION PROCESS (variations) - The proposed compositions and methods for preparation thereof relate to pharmacology, medicine, veterinary science and pharmaceutical industry. The compositions can be used for preparing infusion solutions of antimicrobial (antibacterial and antifungal) preparations increasing therapeutic efficiency thereof. The compositions include nanostructured colloidal silica and are efficient when treating overwhelming sepsis of tested animals. The pharmaceutical compositions have a proven and significant clinically important potentiating impact on therapeutic efficiency of the infusion solution, when treating inflammatory diseases, in comparison with traditional solvents. | 2015-10-08 |
| 20150283175 | SYSTEM FOR TREATING EAR INFECTIONS - Disclosed herein are compositions for treatment of ear infection (such as bacterial and/or yeast infection) in human or veterinary subjects. In some embodiments the compositions include silver microparticles, for example about 0.1% silver microparticles, about 0.2% silver microparticles, or about 0.4% silver microparticles. Also disclosed are methods for treating ear infection in a subject utilizing one or more of the disclosed compositions, for example sequential application of compositions including about 0.1% silver microparticles, about 0.2% silver microparticles, and about 0.4% silver microparticles to the ear canal of the subject. In some examples, one or more of the disclosed compositions are provided in a kit. | 2015-10-08 |
| 20150283176 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCERS COMPRISING DENDRITIC CELLS WITH DAB2 GENE SILENCED - Provided is a pharmaceutical composition for preventing or treating cancer, and more particularly, a pharmaceutical composition for preventing or treating cancer, including dendritic cells with a knock-down Dab2 gene. The composition includes a dendritic cell in which a Dab2 gene is knocked down or knocked out or activity of a Dab2 protein is suppressed as an active ingredient, and thus is expected to be useful as a pharmaceutical composition to prevent, improve or treat cancer as a result of having improved antigen uptake, a migration ability of a cell to a lymph node, and expression of inflammatory cytokines, and activating antigen-specific cytotoxic T cell lymphocyte (CTL) and related T cells that can attack cancer cells, and therefore is expected to be used as the pharmaceutical composition for preventing, improving or treating cancer. | 2015-10-08 |
| 20150283177 | Compositions and Methods Including Recombinant B Lymphocyte Cell Line Including at Least One Endogenous Gene Expressing at Least One Endogenous Membrane Immunoglobulin Reactive to a First Antigen and Including at Least One Exogenously Incorporated Nucleic Acid Expressing at Least One Exogenous Secreted Immunoglobulin Reactive to a Second Antigen - Compositions and methods are disclosed herein for producing one or more immunoglobulins in an isolated B lymphocyte cell line. An isolated recombinant cell line includes an isolated B lymphocyte cell line capable of expressing at least one endogenous membrane immunoglobulin reactive to a first antigen and at least one exogenously incorporated nucleic acid encoding at least one secreted immunoglobulin reactive to a second antigen. | 2015-10-08 |
| 20150283178 | TREATMENT OF CANCER USING ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR - The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a kinase inhibitor, e.g., a kinase inhibitor described herein. The invention also provides kits and compositions described herein. | 2015-10-08 |
| 20150283179 | SELECTING FETAL BOVINE SERUM FOR USE IN STEM CELL CULTURE MEDIA AND PREPARING STEM CELL CULTURE - A method of selecting a collection of cells for choosing a fetal bovine serum (FBS) to use in stem cell transplantation is provided. In addition, a method of selecting a fetal bovine serum (FBS) for use in culturing stem cells for transplantation is provided. Furthermore, a culture medium for culturing stem cells for transplantation and a method of stem cell transplantation are provided. | 2015-10-08 |
| 20150283180 | Prevention and Treatment of Transplant Rejection with Mesenchymal Stem Cells and/or TSG-6 Protein - A method of preventing or treating rejection of a transplanted cell, tissue, or organ in an animal by administering to the animal a composition comprising an effective amount of mesenchymal stem cells and/or at least one anti-inflammatory protein or biologically active fragment, derivative, or analogue thereof. | 2015-10-08 |
| 20150283181 | SELECTING FETAL BOVINE SERUM FOR USE IN STEM CELL CULTURE MEDIA AND PREPARING STEM CELL CULTURE - A method of selecting a collection of cells for choosing a fetal bovine serum (FBS) to use in stem cell transplantation is provided. In addition, a method of selecting a fetal bovine serum (FBS) for use in culturing stem cells for transplantation is provided. Furthermore, a culture medium for culturing stem cells for transplantation and a method of stem cell transplantation are provided. | 2015-10-08 |
| 20150283182 | INJECTABLE ALLOGRAFT PUR COMPOSITE CARRYING rhBMP2 - Embodiments of the present inventions comprise composites of bone particles and polyurethane(s), as well as methods of making such composite and uses thereof. Certain embodiments further comprise a growth factor that can be provided in powder form. Growth factors may be bone morphogenic proteins, such as rhBMP-2. A porous composite comprises a plurality of bone particles, polyurethanes with which the bone particles are combined, and at least one growth factor. A composition may be moldable and/or injectable. After implantation or injection, a composition may be set to form a porous composite that provides mechanical strength and supports the in-growth of cells. Inventive composites have the advantage of being able to fill irregularly shape implantation site while at the same time being settable to provide the mechanical strength for most orthopedic applications. | 2015-10-08 |
| 20150283183 | METHODS FOR TREATING CARDIAC CONDITIONS - Described herein are compositions and methods of treating a cardiac condition using modified placental tissue or an extract of a placental tissue, capable of recruiting stem cells or promoting healing in vivo and in vitro. | 2015-10-08 |
| 20150283184 | Placental Stem Cells Derived From Post-Partum Mammalian Placenta, And Uses And Methods Of Treatment Using Said Cells - The present invention provides compositions and methods of using placental stem cells that originate from a post-partum placenta with conventional cord blood compositions or other stem or progenitor cells. The placental stem cells can be used alone or in a mixture with other stem cell populations. In accordance with the present invention, the placental stem cells may be mixed with other stem cell populations, including but not limited to, umbilical cord blood, fetal and neonatal hematopoietic stem cells and progenitor cells, human stem cells and progenitor cells derived from bone marrow. The placental stem cells and the mixed populations of placental stem cells and stem cells have a multitude of uses and applications, including but not limited to, therapeutic uses for transplantation and treatment and prevention of disease, and diagnostic and research uses. | 2015-10-08 |
| 20150283185 | BACTERIA STRAINS HAVING A HIGH ANTI-INFLAMMATORY ACTIVITY - The present invention relates to probiotic bacteria strains having a high anti-inflammatory activity. The present invention relates to bacteria strains as strongly inducers of Interleukin-10 (IL-10) production. In particular, the present invention relates to the anti-inflammatory activity shown by said bacteria strains due to its enhancement of IL-10 production in peripheral blood mononuclear cells, with on the other hand a low capability to stimulate the production of the pro-inflammatory Il-12, thus leading to a high IL-10/IL-12 ratio. Further, the present invention relates to the use of at least one bacterium strain for the preparation of a composition for the prevention or treatment of the inflammatory bowel diseases (IBD) and irritable bowel syndrome (IBS). Finally, the present invention relates to food products, such as probiotic dietary supplements containing at least one probiotic bacterium strain, as an active ingredient. | 2015-10-08 |
| 20150283186 | Lactobacillus Rhamnosus Strain for Reducing Body Fat Accumulation - The invention relates to the use of | 2015-10-08 |
| 20150283187 | AGENT FOR ALLEVIATING STRESS-INDUCED BOWEL DISORDER CONTAINING SPECIFIC LACTOBACILLUS GASSERI STRAIN OR TREATED PRODUCT THEREOF - The present application provides | 2015-10-08 |
| 20150283188 | METHOD FOR THE EFFICIENT AND CONTINUOUS GROWTH AND HARVESTING OF NUTRIENT-RICH PHYTOPLANKTON AND METHODS OF USING THE SAME - Methods of growing and harvesting multiple species of phytoplankton are disclosed herein. The method generally includes four steps, namely: (1) collecting phytoplankton seawater containing multiple species of naturally-occurring phytoplankton directly from a source of seawater; (2) adding nutrients to the phytoplankton seawater to proliferate the multiple species of naturally-occurring phytoplankton to a predetermined density; (3) separating the multiple species of naturally-occurring phytoplankton from the phytoplankton seawater to form a phytoplankton concentrate; and (4) collecting the phytoplankton concentrate such that the collected phytoplankton of the phytoplankton concentrate remain in a substantially intact cellular state. | 2015-10-08 |
| 20150283189 | MEDICAMENT FOR TREATING MUSCLE AND SKELETAL DISEASES - The present invention concerns the field of therapy of muscle, joint and/or skeletal diseases. In particular, the invention relates to a composition comprising a first solution comprising preparations of | 2015-10-08 |
| 20150283190 | PLANT COMPOSITIONS AND METHODS AND USES THEREOF FOR TREATING ELEVATED GLUCOCORTICOID RELATED DISORDERS, AND ANXIETY - The disclosure provides compositions containing preparations from plants of the family Marcgraviaceae and from plants of the family Platanaceae. The disclosure also provides methods and uses of plant preparations for treating anxiety, stress and glucocorticoid related disorders. | 2015-10-08 |
| 20150283191 | Method of Treating Neurological Conditions with Extract of Nerium Species or Thevetia Species - A method of treating neurological condition in a subject by administration of an extract, or fraction or sub-fraction thereof, of | 2015-10-08 |
| 20150283192 | COMPOSITION AND METHOD FOR ENHANCING ALCOHOL METABOLISM - Disclosed is a composition for enhancing alcohol metabolism in a subject, who overdrank, the composition comprises an effective amount of ginsenoside-free extract of steam-dried Korean ginseng berry (GFM) and one or more pharmaceutically or sitologically acceptable carriers. The composition of the present disclosure may be effective for alleviating hangover according to overdrink and for protecting liver from alcoholic injure. | 2015-10-08 |
| 20150283193 | Compositions for Alleviating Inflammation and Oxidative Stress in a Mammal - An antioxidant-promoting composition that increases antioxidant defense potential in a subject is disclosed. The composition contains | 2015-10-08 |
| 20150283194 | METHOD FOR TREATING PAIN WITH ASTER EXTRACT - Disclosed herein is the use of an extract from an Aster species for the preparation of a medicament for the treatment of pain. The extract is extracted from fresh and/or dried roots and rhizomes of a Tatarian aster ( | 2015-10-08 |
| 20150283195 | Composition Comprising Natural Substance Extract as Active Ingredient for Preventing or Treating Acute Renal Failure - Disclosed is a composition including an | 2015-10-08 |
| 20150283196 | METHOD FOR MANUFACTURING COMPOSITION CONTAINING NOBILETIN AND TANGERETIN DERIVED FROM CITRUS FRUITS, AND COMPOSITION CONTAINING NOBILETIN AND TANGERETIN OBTAINED THEREBY - The object of the invention is to provide a method of manufacturing a fraction containing nobiletin and tangeretin at high concentrations, which is excellent in terms of safety, economic efficiency, and the potential for industrialization. | 2015-10-08 |
| 20150283197 | Pharmaceutical compositions for treating cancer of genital system and preparation method therefor - A pharmaceutical composition for preventing and treating cancer of reproductive system and preparation method therefor. The pharmaceutical composition is prepared using one or more of the following as raw material: | 2015-10-08 |
| 20150283198 | Methods for Treating HCV - The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof. | 2015-10-08 |
| 20150283199 | Methods for Treating HCV - The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of interferon, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof. | 2015-10-08 |
| 20150283200 | METHODS FOR TREATMENT OF ATHEROSCLEROSIS - Disclosed herein are methods and compositions for preventing or treating atherosclerosis in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide and, in some applications, a second active agent, to subjects in need thereof. The present technology relates to the treatment or prevention of atherosclerosis in mammals through the administration of a therapeutically effective amount of aromatic cationic peptides and, in some embodiments, a second active agent. | 2015-10-08 |
| 20150283201 | IMPLANTABLE DEVICE FOR THE DELIVERY OF OCTREOTIDE AND METHODS OF USE THEREOF - This invention is related to the use of polyurethane-based polymer as a drug delivery device to deliver biologically active octreotide at a constant rate for an extended period of time and methods of manufactures thereof. The device is very bio-compatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of octreotide to tissues or organs. | 2015-10-08 |
| 20150283202 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA, ATHEROSCLEROSIS, CORONARY HEART DISEASE, GALLSTONE, OBESITY AND OTHER CARDIOVASCULAR DISEASES - This invention also provides a method to prevent, control, and treat a lipid metabolism disorder, a billary disorder, cardiovascular disease, obesity or an endocrine disorder by administering at least one agonist of guanalyte cyclase receptor either alone or in combination with a compound typically used to treat the disorder and or with an an inhibitor of cGMP-dependent phosphodieasterases. | 2015-10-08 |
| 20150283203 | METHOD FOR TREATING PROSTATITIS UTILIZING PORE-FORMING PROTEIN PROAEROLYSIN - The present disclosure includes methods and compositions for treating any condition involving prostatitis and similar diseases and/or conditions. These methods and compositions involve the use of targeted modified pore-forming proteins, including variant proaerolysin proteins. | 2015-10-08 |
| 20150283204 | Anti-Pathogenic Methods - The present disclosure teaches the protection of plants and human and non-human subjects from pathogens. The present disclosure enables a multivalent approach to inhibiting pathogen infection in plant and human and non-human animal subjects and to ameliorate damage to susceptible subjects. | 2015-10-08 |
| 20150283205 | THY1 (CD90) AS A NOVEL THERAPY TO CONTROL ADIPOSE TISSUE ACCUMULATION - The present invention relates to methods of treating a condition involving excessive adipogenesis. This method relates to selecting a subject having a condition involving excessive adipogenesis and administering to the selected subject a composition comprising a Thy1 protein or polypeptide fragment thereof, or an agent that enhances Thy1 expression, under conditions effective to treat the condition. The present invention also relates to isolated nucleic acid molecules encoding a Thy1 protein or the fragment thereof and pharmaceutical formulations including such a protein or fragment thereof or an agent that enhances Thy1 expression and a pharmaceutically acceptable carrier. The present invention also relates to methods of inhibiting adipogenesis and/or decreasing adipocyte size, as well as methods of screening a candidate compound for its ability to influence adipogenesis. | 2015-10-08 |
| 20150283206 | Treatment selection for lung cancer patients using mass spectrum of blood-based sample - A test for predicting whether a non-small-cell lung cancer patient is more likely to benefit from an EGFR-I as compared to chemotherapy uses a computer-implemented classifier operating on a mass spectrum of a blood-based sample obtained from the patient. The classifier makes use of a training set which includes mass spectral data from blood-based samples of other cancer patients who are members of a class of patients predicted to have overall survival benefit on EGFRI-Is, e.g., those patients testing VS Good under the test described in U.S. Pat. No. 7,736,905. This class-labeled group is further subdivided into two subsets, i.e., those patients which exhibited early (class label “early”) and late (class label “late”) progression of disease after administration of the EGFR-I in treatment of cancer. | 2015-10-08 |
| 20150283207 | TEAR LIPOCALIN MUTEINS BINDING IL-4 R ALPHA - The present invention relates to novel muteins derived from human tear lipocalin, which bind to IL 4 receptor alpha. The sequences of the muteins comprise particular combinations of amino acids. In particular a mutated amino acid residue is present at any one or more of the sequence positions 27, 28, 30, 31, 33, 53, 57, 61, 64, 66, 80, 83, 104-106 and 108 of the linear polypeptide sequence of the mature human tear lipocalin. A mutated amino acid residue is also present at any 2 or more of the sequence positions 26, 32, 34, 55, 56, 58 and 63 of the linear polypeptide sequence of the mature human tear lipocalin. The invention also provides a corresponding nucleic acid molecule encoding such a mutein and a method for producing such a mutein and its encoding nucleic acid molecule. | 2015-10-08 |
| 20150283208 | METHODS OF INHIBITING SURFACE ATTACHMENT OF MICROORGANISMS - The invention provides, inter alia, methods of inhibiting virulence of one or more microorganisms, and/or inhibiting one or more microorganisms from attaching to a surface, forming suspended aggregates or a combination thereof, by contacting the one or more microorganisms, the surface, or a combination thereof with a mucin, such as e.g., a purified, native, non-human mucin. | 2015-10-08 |
| 20150283209 | ACTIVIN-ACTRII ANTAGONISTS AND USES FOR TREATING BONE AND OTHER DISORDERS - Provided herein are methods for the treatment of bone disorders that are associated with kidney disease wherein the methods comprise administration of Activin-ActRIIA inhibitors to a subject in need of the treatment. Also provided herein are methods and compositions for the treatment of low turnover bone disorders wherein the methods comprise administration of Activin-ActRIIA inhibitors to a subject in need of the treatment. Further provided herein are compositions for the treatment of bone disorders that are associated with kidney disease and compositions for the treatment of low turnover bone disorders and vascular calcification. | 2015-10-08 |
| 20150283210 | Controlled Release Of Growth Factors And Signaling Molecules For Promoting Angiogenesis - The present invention comprises compositions, methods, and devices for delivering angiogenic factors and signaling molecules to a target tissue, and controlling the release of these factors and signaling molecules to spatially and temporally restrict their release and dissemination, for the purpose of promoting angiogenesis in target tissues wherein increased blood supply is needed. | 2015-10-08 |
| 20150283211 | METHODS FOR TREATING A SPINAL DISORDER OR OSTEOARTHRITIS USING DOMINANT NEGATIVE TISSUE NECROSIS FACTOR - Effective methods of treating a spinal disorder or osteoarthritis associated with a proinflammatory agent in a patient in need of such treatment, the method comprising administering an effective amount of DN-TNF (e.g., XPro®-1595) to a target tissue site at or near the spine or osteoarthritic joint to reduce pain and/or inflammation. | 2015-10-08 |
| 20150283212 | ORAL CALCITONIN COMPOSITIONS AND APPLICATIONS THEREOF - The present invention relates to compositions for the oral delivery of pharmacologically active calcitonin, to methods of synergistically enhancing the biological effects of orally administered calcitonin with D type vitamins and calcium, and to methods of treating and/or preventing disease in mammals, particularly humans, by orally administering calcitonin compositions in accordance with the invention. | 2015-10-08 |
| 20150283213 | METHOD FOR TREATING HYPERGLYCEMIA WITH GLP-1 - A method for treating hyperglycemia and/or diabetes in a subject is provided. In particular, the method is directed for the treatment of patients with type 2 diabetes mellitus who have a fasting blood glucose concentration greater than about 8 mM, wherein the patient is administered a formulation comprising a GLP-1 molecule and a diketopiperazine by pulmonary inhalation with a dry powder inhalation system. | 2015-10-08 |
| 20150283214 | CHIMERIC FIBRONECTIN MATRIX MIMETICS AND USES THEREOF - The present invention is directed to recombinant fibronectin peptide mimetics and wound healing compositions containing the same. Other aspects of the present invention include wound healing dressings that comprise the wound healing composition of the present invention and a wound dressing material and methods of treating wounds using these compositions. | 2015-10-08 |
| 20150283215 | METHOD TO INCREASE THE GROWTH VELOCITY OF HUMAN INFANTS - The present invention relates to a method to increase the growth velocity of a human infant, said method comprising the enteral administration to said infant of recombinant human bile-salt-stimulated lipase (rhBSSL). Such method has particular utility for underweight or preterm human infants, particular those in medical need of increasing their growth velocity. The invention also relates to compositions, including infant feeds, kits, packaged-pharmaceutical-products and pharmaceutical compositions, and also to methods to prepare infant feeds. In another aspect, the present invention relates to methods to: (X) protect the small bowel mucosa of a human infant from damage; to (Y) protect an immature intestinal epithelium of a human infant from the deleterious effects of incompletely digested and/or excess fat and/or lipid; and/or to (Z) limit accumulation of incompletely digested and/or excess fat and/or lipid in the ileum of a human infant; said methods in each case comprising the step of enteral administration of rhBSSL. | 2015-10-08 |
| 20150283216 | STABILIZED COMPOSITIONS OF PROTEINS HAVING A FREE THIOL MOIETY - Compositions of proteins having free thiols, and methods of making and using such compositions, are described. | 2015-10-08 |
| 20150283217 | STABLE THERMOLYSIN HYDROGEL - Disclosed is a hydrogel comprising a hydrophilic gelling agent that includes a nonionic cellulose ether, and active thermolysin, wherein the proteolytic activity of the thermolysin does not decrease by more than 20% when stored at room temperature for 6 months. | 2015-10-08 |
| 20150283218 | PEPTIDE CONJUGATED PARTICLES - The present invention provides compositions comprising peptide-coupled biodegradable poly(lactide-co-glycolide) (PLG) particles In particular, PLG particles are surface-functionalized to allow for coupling of peptide molecules to the surface of the particles (e.g., for use in eliciting induction of immunological tolerance). | 2015-10-08 |
| 20150283219 | UNIVERSAL CANCER PEPTIDES DERIVED FROM TELOMERASE - The invention relates to a peptide of 15 to 20 amino acids deriving from TERT protein, which peptide is capable of (i) binding to HLA class II and (ii) stimulating a CD4 Th response. These universal cancer peptides are especially useful in anti-tumor immunotherapy and immunomonitoring. | 2015-10-08 |
| 20150283220 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER - Provided herein are vaccine compositions having potent adjuvant activity. Such compositions are capable of increasing anti-gen-specific antibody responses and increased frequency of Her-2-specific CD4+ T-cells, have improved anti-tumor efficacy, and are useful in methods of treating cancer. | 2015-10-08 |
| 20150283221 | ATTENUATED LISTERIA MONOCYTOGENES MUTANT AS A VACCINE VECTOR FOR THE DELIVERY OF EXOGENEOUS ANTIGENS - Vaccines and compositions containing an attenuated | 2015-10-08 |
| 20150283222 | PCV/Mycoplasma Hyopneumoniae Combination Vaccine - This invention provides a multivalent immunogenic composition including a soluble portion of a | 2015-10-08 |
| 20150283223 | Novel Immunogenic Antigens of Shigella - A vaccine for protection against multiple serotypes of | 2015-10-08 |
